

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Canceled)
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Canceled)
9. (Canceled)
10. (Canceled)
11. (Canceled)
12. (Canceled)
13. (Canceled)
14. (Canceled)
15. (Canceled)
16. (Canceled)
17. (Canceled)
18. (Canceled)
19. (Currently amended) A method for producing a high titer antibody producing cell *in vitro* comprising ~~suppressing the expression of alpha-1-anti-trypsin, or endothelial monocyte activating polypeptide I, or both in an antibody producing cell,~~ introducing into an antibody-producing mammalian cell a polynucleotide that disrupts the function of a gene encoding alpha-1-antitrypsin, a polynucleotide that disrupts the function of a gene encoding endothelial monocyte activating polypeptide I, or both, wherein such that the cell expresses a higher titer of an antibody as compared with identical cells into which said polynucleotide that disrupts the function of a gene encoding alpha-1-antitrypsin, said polynucleotide that disrupts the function of a gene encoding endothelial monocyte activating polypeptide I, or both has not been introducedin which such suppression has not occurred.

20. (Original) The method of claim 19 wherein the cell is a hybridoma.
21. (Withdrawn) The method of claim 19 where in the cell is an epithelial cell.
22. (Withdrawn) The method of claim 19 where in the cell is ovarian.
23. (Withdrawn) The method of claim 19 where in the cell is a kidney cell.
24. (Withdrawn) The method of claim 19 where in the cell is a myeloid cell.
25. (Withdrawn) The method of claim 19 where in the cell is a lymphoid cell.
26. (Canceled)
27. (Withdrawn; currently amended) The method of claim 19 ~~26~~ wherein the polynucleotide that disrupts the function of a gene encoding alpha-1-antitrypsin comprises an expression vector comprising an antisense transcript to a gene encoding alpha-1-antitrypsin and wherein the polynucleotide that disrupts the function of a gene encoding endothelial monocyte activating polypeptide I, ~~suppressing~~ comprises introducing into the cell an expression vector comprising an antisense transcript to a ~~gene~~ genes encoding endothelial monocyte-activating polypeptide I, ~~alpha-1-anti-trypsin, or both.~~
28. (Currently amended) The method of claim 19 wherein said polynucleotide that disrupts the function of a gene encoding alpha-1-antitrypsin comprises the suppressing ~~comprises introducing into the cell~~ a knock out targeting vector to disrupt the function of a ~~gene~~ genes encoding endothelial monocyte activating polypeptide I, alpha-1-anti-trypsin and wherein the polynucleotide that disrupts the function of a gene encoding endothelial monocyte activating polypeptide I comprises a knock out targeting vector to disrupt the function of a gene encoding endothelial monocyte activating polypeptide I, ~~or both.~~
29. (Canceled)
30. (Canceled)
31. (Canceled)
32. (Canceled)
33. (Canceled)
34. (Canceled)
35. (Canceled)
36. (Canceled)
37. (Canceled)
38. (Canceled)

DOCKET NO.: MOR-0241
Application No.: 10/624,631
Office Action Dated: August 29, 2007

PATENT

- 39. (Canceled)
- 40. (Canceled)
- 41. (Canceled)
- 42. (Canceled)
- 43. (Canceled)
- 44. (Canceled)
- 45. (Canceled)
- 46. (Canceled)
- 47. (Canceled)
- 48. (Canceled)
- 49. (Canceled)
- 50. (Canceled)
- 51. (Canceled)
- 52. (Canceled)
- 53. (Canceled)
- 54. (Canceled)
- 55. (Canceled)
- 56. (Canceled)
- 57. (Canceled)
- 58. (Canceled)
- 59. (Canceled)
- 60. (Canceled)
- 61. (Canceled)
- 62. (Canceled)
- 63. (Canceled)
- 64. (Canceled)
- 65. (Canceled)
- 66. (Canceled)
- 67. (Canceled)
- 68. (Canceled)
- 69. (Canceled)

- 70. (Canceled)
- 71. (Canceled)
- 72. (Previously Presented) The method of claim 19, wherein the cell is a rodent cell.
- 73. (New) The method of claim 19, wherein said alpha-1-antitrypsin comprises an amino acid sequence of SEQ ID NO:21, 22, 23, 24, 25, 26, or 27 and said endothelial monocyte activating polypeptide I comprises an amino acid sequence of SEQ ID NO: 28, 29, 30, 31, 32, 33, or 34.